Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...
Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move ...
Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...
In this MedPage Today video, Taylor Brooks, MD, of the Cleveland Clinic Cancer Institute, discusses real-world survival ...
MedPage Today on MSN
Bispecifics Before CAR-T May Be Best-Bet Sequence for Large B-Cell Lymphoma
The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal ...
Lymphatic malformations (LMs) are congenital vascular anomalies characterized by abnormal lymphatic development, leading to ...
Autolus will evaluate Cellares’ fully automated, high-throughput manufacturing platform in preparation for expansion into new indicationsSOUTH SAN FRANCISCO, Calif. and LONDON, Jan. 06, 2026 (GLOBE ...
In hepatitis B virus (HBV) infection, the capacity to mount a functional virus-specific T-cell response has long been considered the principal, if not the sole, immunological determinant of viral ...
News-Medical.Net on MSN
Epigenetic plasticity in germinal center B cells may help explain lymphoma origins
Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...
During a live event, Matthew Lunning, DO, interpreted long-term outcomes of the ZUMA-7 and TRANSFORM trials.
A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback